Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04940884
Other study ID # 201602058A3C502
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date January 31, 2022

Study information

Verified date July 2022
Source Chang Gung Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Altered circulating microRNA (miRNA) after physical activity reflects exercise effects on muscle performance and cardiorespiratory fitness. The present work was designed to highlight associations between exercise-induced physical fitness miRNAs in community-indwelling elderly adults. Baseline clinical information was assessed for community-indwelling individuals, long-term followed by our community medicine research center, aged >=55 years near our hospital. Among them, participants were randomly assigned to the supervised exercise training (SET) and home exercise training (HET) groups. All included subjects were instructed to walk>=8000 steps per day (stp/d), which was recorded by wrist-worm smart watches. SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session. HET participants underwent walking activities as the above instruction. Movement analysis and body composition measurements were used to assess physical fitness at baseline and 8 as well as 24 weeks after recruitment. MiRNAs (miR-21, miR-126, miR-146a, and miR-222) were also examined at the above time point. SET participants took significantly more steps per day and had greater chance to walk>=8000 stp/d in the community compared to the SET participants during follow-up. Prominent beneficial effects on physical fitness, including cardiorespiratory fitness, flexibility, lower extremity muscle strength, and body composition, were noticed during and 16 weeks after stopping SET. Increased miR146a and miR-126 expressions reflecting increased anti-inflammatory response and enhanced angiogenesis, respectively after 8 weeks of SET. However, inhibited skeletal as well as cardiac muscle catabolism respectively reflecting in the increased miR-21 and miR-222 were also identified in the present work. These observations may clarify short-term SET effects on lifestyle in community inhabitants and how sensitive of miRNAs to exercise-induced physiological adaptations.


Description:

Design The Institutional Review Board of a tertiary care hospital approved the study (IRB No.: 201602058A3C502 and NCT04839796). A randomized controlled trial with assessor and subject blinded study for effects of exercise regimens on ageing persons was performed from May to November 2021. All subjects provided informed consent after understanding the experimental procedures. Participants were then randomly allocated to undergo 30 min of supervised exercise training (SET) at moderate-intensity continuous training (MICT) for 24 sessions in the hospital or home exercise training (HET) groups using a computer-generated, concealed allocation schedule. Data were collected by a blinded assessor prior to randomization and after completing the exercise training. Participants Community-indwelling individuals with age>=55 years, who lived adjacent to a community hospital were surveyed. Elderly adults with mini-mental state examination (MMSE) score > 24 and negative lumbar spine as well as lower extremity degenerative joint disorder were recruited. Those who had unstable clinical presentations mentioned in our previous studies, or sarcopenia, diagnosed based on the recommendation of the Asian Working Group for Sarcopenia, were not candidates of the study. We also excluded individuals with absolute contraindications for aerobic activities, suggested by the American College of Sports Medicine (ACSM). The baseline physical component score (PCS) and mental component scores (MCS) in the Medical Outcomes Study Short Form 36 (SF-36) were used to assess the quality of life (QoL) and were re-evaluated 24 weeks after the recruitment. Baseline demographic characteristics and clinical information of included participants were carefully recorded. Exercise Training All subjects were instructed to wear a smart watch (WDI08, WisDat Inc., Taichung, Taiwan) and to take at least 8000 steps per day (stp/d). In addition to 8000 stp/d, the SET participants underwent 24 sessions of supervised MICT (70% of maximum predicted HR) for 30-min on a bicycle ergometer (Ergoselect 150P, ergoline GmbH, Bitz, Germany) in our hospital during an 8-week period. All subjects were reminded to take >=8000 stp/d every week during the first 8-week after recruitment by phone call and app. After completing the MICT, SET participants were instructed to take >=8000 stp/d for another 16 weeks. HET participants were instructed to take 8000 stp/d over the 24-week follow-up period. During the latter 16-week, the instruction of taking>=8000 stp/d was not reminded in all subjects. The exercise training was terminated when the subject had symptoms/signs during exercise according to the ACSM guideline.20 Measurement of physical fitness The wrist-worn smart watch (WDI08, Wisdat Inc., Taichung, Taiwan) recorded the every-day step count and energy expenditure in each subject, and the average number of steps and energy expenditure (Kcal) per day in a week represented the mean every day steps and energy expenditure of a week in community during the 24-week follow-up period. The calf circumference (Calf_circ) was obtained by averaging the greatest Calf_circ in bilateral legs. Intelligent movement analysis (eFitHealth, uCare Medical Electronics, Co. Ltd., Miaoli, Taiwan) using interactive voices and 3D depth image guides to assess 2-min step number, 5-time sit-to-stand duration, and chair sit-and-reach distance (Supplementary Data 1). Each of the above test was used to estimate VO2max (eV O2max), lower extremity muscle strength, and flexibility, respectively.21 Body composition, including total body water (TBW), mineral portion, protein amount (Prot), lean body mass (LBM), skeletal muscle mass (SKM), body fat mass (BFM), and basal metabolic rate (BMR) were measured by multiple frequency bioimpedance analysis (Inbody 720, Inbody Co., Ltd., CA, USA). The above measurements were documented before, 8-week after, and 24-week after initial visit. RNA extraction Blood sampling of 10 ml whole blood from each subject at the recruitment, 8-week, and 24-week from the initial visit was placed in a tube containing 3.2% sodium citrate. Samples were then centrifuged at 360xg for 15 min, which supernatant was further centrifuged at 2400xg for 20 min at room temperature of 25 ℃ to keep plasma platelet count less than 2.5×10^8/ml. Processed plasma of 400 microL was placed in a 2mL eppendorf (Eppendorf corp. Hamburg, Germany) to mix with 1200 microL TRIzol (ThermoFisher Scientific Inc., Waltham, MA, USA) and 5 microL miR-39 (5x10^-15 mol/microL), exogenous control, of C. elegans as well as 2 microg (10 microg/mL in plasma) yeast RNA (Invitrogen, Carlsbad, CA, USA) for 15 min at room temperature. Another 320 microL chloroform was added and placed at room temperature for 5 min. The specimen was centrifuged at 12000 xg for 15 min at 4 ℃ and 300 microL colorless fluid layer was aspirated to mix with 900 microL iced 100% ethanol overnight at -80 ℃. The prepared specimen was placed into the Direct-zol column (Direct-zol RNA Miniprep, Zymo Research corp., Irvine, CA, USA) and was then centrifuged at 12000 xg for 30 sec. The column was then transferred to a new collection tube and was centrifuged at 12000 xg for 30 sec after mixing with 400 microL RNA wash buffer. DNase I reaction mix of 80 microL (DNase I enzyme 5 microL+DNA digestion buffer 75 microL) was added to the tube after discarding the RNA wash buffer and was incubated at room temperature for 15 min. Additional 400 microL pre-wash buffer was introduced into the tube and was centrifuged at 12000 xg for 30 sec. The column was then transferred into a new 1.5 mL RNase-free tube and was treated with 80 microL nuclease-free water at room temperature for 2min. The prepared sample was centrifuged at 12000 xg for 2 min to elute RNA solution. Quantification of plasma microRNA levels miR-21, miR-126, miR-146a and miR-222 levels at the above three different time was analyzed. One-step real-time quantitative polymerase chain reaction (RT-qPCR) was performed using a RT-qPCR system (T100TM Thermal Cycler, Bio-Rad Laboratories Inc., Berkeley, CA, USA) to assess plasma microRNA levels. A mixture of 100 ng total RNA extraction, 10 microL TaqMan master mix (ThermoFisher), 5.8 microL nuclease-free water, 0.2 microL universal probe library 21 (10 microM), 0.1 microL RNase inhibitor, self-constructed 1 microL forward primers and 1 microL reverse primers for miR-39, miR-126 and miR-146a, and 2 microL cDNA template were created on ice. All reactions were incubated in a 48-well plate at 95°C for 3 min, followed by 40 cycles of 95°C for 5 sec, 60°C for 10 sec and 72°C for 1 sec. Self-constructed forward and reverse primer sequences for primary C. elegans miR-39 (C-miR-39) as exogenous control. Human miR-126 (miR-126) and miR-146a (miR-146a) (Supplementary Table 1) were normalized by the exogenous control and were used to determine the microRNA levels expressions during the follow-up. miRCURY LNA SYBR Green PCR kit (Qiagen) was used to determine human miR-21 (miR-21) and miR-222 (miR-222). A mixture of 4 microL 5X miRCURY RT SYBR Green Reaction Buffer, 2 microL 10X miRCURY RT Wnzyme Mix and 14 microL of 100 ng total RNA extraction in nuclease-free water was incubated in a 48-well plate at 42°C for 60 min and followed by 95°C to generate cDNA. A mixture containing 2 microL C-miR-39 (or miR-21/ or miR-222) primers purchased from Qiagen, 10 microL miRCURY SYBR Green Master Mix, 2 microL nuclease-free water and 6 microL 5X generated cDNA template was incubated at 95°C for 2 min, followed by 40 cycles of 95°C for 10 sec and 56°C for 60 sec. has-miR-21 and hsa-miR-222 were normalized by the C-miR-39 and were used to determine the microRNA levels expressions during the follow-up. Determination of inflammatory activity 300 microL of serum was diluted by 1:2 ratios. Loaded 50 microL of prepared samples per well and calibrators in duplicate onto the assay plate (Multiplex Human Cytokine Panel 1, Boster Biological Technology, Pleasanton, CA, USA). Each well containing antibodies captured IL-1α, IL-1β, IL-6, IL-10, and TNFα. A mixture that contains biotinylated analyte specific antibodies is added after washing away any unbound protein. The biotinylated antibodies completed the sandwich for each specific arrayed analyte. After washing away unbound biotinylated antibody, streptavidin horseradish peroxidase (SHRP) is added. Following an additional wash, the amount of SHRP remaining on each location of the array is proportional to the amount of the above initially captured cytokines. The amount of conjugated enzyme on each location of the array is measured with the addition of a chemiluminescent substrate. Statistical analysis Data are presented as mean (95% CI) or n (%). Differences of continuous and nominal parameters and between the two groups were estimated by student-t and chi-square tests, respectively. Repeated measurement ANOVA was conducted to analyze differences of continuous parameters measured at the three time points in each group. Pearson correlation was performed to find the relationship between physical fitness and miRNAs. A p value less than 0.05 was considered as statistical significance.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date January 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria: Primary 1.Community-indwelling individuals with age>=55 years, who lived adjacent to a community hospital were surveyed. Secondary 1. Adults with mini-mental state examination (MMSE) score > 24 2. Negative lumbar spine as well as lower extremity degenerative joint disorder were recruited. Exclusion Criteria: 1. unstable angina 2. unstable BP 3. severe aortic stenosis 4. inflammatory disease within recent 3 months 5. uncontrolled or severe cardiac dysrhythmias 6. uncompensated HF 7. embolic disease within recent 3 months 8. ST segment displacement>=2 mm at rest 9. uncontrolled diabetes 10. sarcopenia 11. Patients with absolute contraindications of exercise training (Pescatello LS, Arena R, Riebe D and Thompson PD. ACSM's guidelines for exercise testing and prescription. 9th ed. Philadelphia, PA.: Wolters Kluwer/Lippincott Williams & Wilkins; 2014.)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Supervised exercise training
SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
Aerobic exercise training
All recruited subjects were instructed to walk >=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.

Locations

Country Name City State
Taiwan Keelung Chang Gung Memorial Hospital Keelung

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary walking steps per day (stp/d) mean every day walking steps in a week measured by a wrist-worn smart watch 24 weeks
Primary energy expenditure per day (Kcal/d) mean every day energy consumption in a week estimated by a wrist-worn smart watch. 24 weeks
Primary estimated maximum oxygen consumption (eVO2max) maximum energy consumption estimated from 2-min step numbers measured by an interactive voices and 3D depth imaging device. Initial recruitment
Primary estimated maximum oxygen consumption (eVO2max) maximum energy consumption estimated from 2-min step numbers measured by an interactive voices and 3D depth imaging device. 8 weeks after recruitment
Primary estimated maximum oxygen consumption (eVO2max) maximum energy consumption estimated from 2-min step numbers measured by an interactive voices and 3D depth imaging device. 24 weeks after recruitment
Primary Calf circumference (cm) Average maximum calf circumference of bilateral legs obtained by measuring tape. Initial recruitment
Primary Calf circumference (cm) Average maximum calf circumference of bilateral legs obtained by measuring tape. 8 weeks after recruitment
Primary Calf circumference (cm) Average maximum calf circumference of bilateral legs obtained by measuring tape. 24 weeks after recruitment
Primary 5-time sit-to-stand duration (second) 5-time sit-to-stand duration measured by an interactive voices and 3D depth imaging device. Initial recruitment
Primary 5-time sit-to-stand duration (second) 5-time sit-to-stand duration measured by an interactive voices and 3D depth imaging device. 8 weeks after recruitment
Primary 5-time sit-to-stand duration (second) 5-time sit-to-stand duration measured by an interactive voices and 3D depth imaging device. 24 weeks after recruitment
Primary Sit-and-reach distance (cm) Hand reaching distance while performing forward bending in a sitting position Initial recruitment
Primary Sit-and-reach distance (cm) Hand reaching distance while performing forward bending in a sitting position 8 weeks after recruitment
Primary Sit-and-reach distance (cm) Hand reaching distance while performing forward bending in a sitting position 24 weeks after recruitment
Primary Normalized total body water content (%) Total body water content obtained from bioimpedance measurement and was then normalized by body weight Initial recruitment
Primary Normalized total body water content (%) Total body water content obtained from bioimpedance measurement and was then normalized by body weight 8 weeks after recruitment
Primary Normalized total body water content (%) Total body water content obtained from bioimpedance measurement and was then normalized by body weight 24 weeks after recruitment
Primary Normalized total mineral content (%) Total body mineral content obtained from bioimpedance measurement and was then normalized by body weight. Initial recruitment
Primary Normalized total mineral content (%) Total body mineral content obtained from bioimpedance measurement and was then normalized by body weight. 8 weeks after recruitment
Primary Normalized total mineral content (%) Total body mineral content obtained from bioimpedance measurement and was then normalized by body weight. 24 weeks after recruitment
Primary Normalized total protein amount (%) Total body protein amount obtained from bioimpedance measurement and was then normalized by body weight. Initial recruitment
Primary Normalized total protein amount (%) Total body protein amount obtained from bioimpedance measurement and was then normalized by body weight. 8 weeks after recruitment
Primary Normalized total protein amount (%) Total body protein amount obtained from bioimpedance measurement and was then normalized by body weight. 24 weeks after recruitment
Primary Normalized body fat mass (%) Total body fat amount obtained from bioimpedance measurement and was then normalized by body weight. Initial recruitment
Primary Normalized body fat mass (%) Total body fat amount obtained from bioimpedance measurement and was then normalized by body weight. 8 weeks after recruitment
Primary Normalized body fat mass (%) Total body fat amount obtained from bioimpedance measurement and was then normalized by body weight. 24 weeks after recruitment
Primary Normalized skeletal mass to lean body mass percentage (%) Total skeletal mass obtained from bioimpedance measurement and was then normalized by lean body mass. Initial recruitment
Primary Normalized skeletal mass to lean body mass percentage (%) Total skeletal mass obtained from bioimpedance measurement and was then normalized by lean body mass. 8 weeks after recruitment
Primary Normalized skeletal mass to lean body mass percentage (%) Total skeletal mass obtained from bioimpedance measurement and was then normalized by lean body mass. 24 weeks after recruitment
Primary miR-21 (relative intensity) Ratio of human micro RNA 21 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. Initial recruitment
Primary miR-21 (relative intensity) Ratio of human micro RNA 21 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 8 weeks after recruitment
Primary miR-21 (relative intensity) Ratio of human micro RNA 21 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 24 weeks after recruitment
Primary miR-126 (relative intensity) Ratio of human micro RNA 126 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. Initial recruitment
Primary miR-126 (relative intensity) Ratio of human micro RNA 126 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 8 weeks after recruitment
Primary miR-126 (relative intensity) Ratio of human micro RNA 126 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 24 weeks after recruitment
Primary miR-146a (relative intensity) Ratio of human micro RNA 146a measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. Initial recruitment
Primary miR-146a (relative intensity) Ratio of human micro RNA 146a measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 8 weeks after recruitment
Primary miR-146a (relative intensity) Ratio of human micro RNA 146a measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 24 weeks after recruitment
Primary miR-222 (relative intensity) Ratio of human micro RNA 222 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. Initial recruitment
Primary miR-222 (relative intensity) Ratio of human micro RNA 222 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 8 weeks after recruitment
Primary miR-222 (relative intensity) Ratio of human micro RNA 222 measured by real-time quantitative polymerase chain reaction compared to the level of microRNA 39 of C. elegans. 24 weeks after recruitment
Primary IL-1a (relative intensity) Ratio of IL-1a obtained from ELISA assay plate at each time point to the baseline level. Initial recruitment
Primary IL-1a (relative intensity) Ratio of IL-1a obtained from ELISA assay plate at each time point to the baseline level. 8 weeks after recruitment
Primary IL-1a (relative intensity) Ratio of IL-1a obtained from ELISA assay plate at each time point to the baseline level. 24 weeks after recruitment
Primary IL-1b (relative intensity) Ratio of IL-1b obtained from ELISA assay plate at each time point to the baseline level. Initial recruitment
Primary IL-1b (relative intensity) Ratio of IL-1b obtained from ELISA assay plate at each time point to the baseline level. 8 weeks after recruitment
Primary IL-1b (relative intensity) Ratio of IL-1b obtained from ELISA assay plate at each time point to the baseline level. 24 weeks after recruitment
Primary IL-6 (relative intensity) Ratio of IL-6 obtained from ELISA assay plate at each time point to the baseline level. Initial recruitment
Primary IL-6 (relative intensity) Ratio of IL-6 obtained from ELISA assay plate at each time point to the baseline level. 8 weeks after recruitment
Primary IL-6 (relative intensity) Ratio of IL-6 obtained from ELISA assay plate at each time point to the baseline level. 24 weeks after recruitment
Primary IL-10 (relative intensity) Ratio of IL-10 obtained from ELISA assay plate at each time point to the baseline level. Initial recruitment
Primary IL-10 (relative intensity) Ratio of IL-10 obtained from ELISA assay plate at each time point to the baseline level. 8 weeks after recruitment
Primary IL-10 (relative intensity) Ratio of IL-10 obtained from ELISA assay plate at each time point to the baseline level. 24 weeks after recruitment
Primary TNFa (relative intensity) Ratio of IL-10 obtained from ELISA assay plate at each time point to the baseline level. Initial recruitment
Primary TNFa (relative intensity) Ratio of IL-10 obtained from ELISA assay plate at each time point to the baseline level. 8 weeks after recruitment
Primary TNFa (relative intensity) Ratio of IL-10 obtained from ELISA assay plate at each time point to the baseline level. 24 weeks after recruitment
Primary Physical component score (PCS) Physical role function obtained from short form 36 questionnaire (SF-36) before and after exercise training. The SF-36 consists of eight scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. Initial recruitment
Primary Physical component score (PCS) Physical role function obtained from short form 36 questionnaire (SF-36) before and after exercise training. The SF-36 consists of eight scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. 24 weeks after recruitment
Primary Mental component score (MCS) Mental health score obtained from short form 36 questionnaire (SF-36) before and after exercise training. The SF-36 consists of eight scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. Initial recruitment
Primary Mental component score (MCS) Mental health score obtained from short form 36 questionnaire (SF-36) before and after exercise training. The SF-36 consists of eight scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. 24 weeks after recruitment
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A